This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Combination of subtherapeutic anti-TNF dose with dasatinib restores clinical and molecular arthritogenic profiles better than standard anti-TNF treatment
Journal of Translational Medicine Open Access 23 April 2021
-
The Src family kinase inhibitor dasatinib delays pain-related behaviour and conserves bone in a rat model of cancer-induced bone pain
Scientific Reports Open Access 06 July 2017
-
Pathobiology and management of prostate cancer-induced bone pain: recent insights and future treatments
Inflammopharmacology Open Access 06 August 2013
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Shah NP, Tran C, Lee FY, Chen P, Norris D, Sawyers CL . Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 2004; 305: 399–401.
Melnick JS, Janes J, Kim S, Chang JY, Sipes DG, Gunderson D et al. An efficient rapid system for profiling the cellular activities of molecular libraries. Proc Natl Acad Sci USA 2006; 103: 3153–3158.
Hochhaus A, Kantarjian HM, Baccarani M, Lipton JH, Apperley JF, Druker BJ et al. Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. Blood 2007; 109: 2303–2309.
Dewar AL, Cambareri AC, Zannettino AC, Miller BL, Doherty KV, Hughes TP et al. Macrophage colony-stimulating factor receptor c-fms is a novel target of imatinib. Blood 2005; 105: 3127–3132.
Dewar AL, Farrugia AN, Condina MR, Bik To L, Hughes TP, Vernon-Roberts B et al. Imatinib as a potential antiresorptive therapy for bone disease. Blood 2006; 107: 4334–4337.
Dai XM, Ryan GR, Hapel AJ, Dominguez MG, Russell RG, Kapp S et al. Targeted disruption of the mouse colony-stimulating factor 1 receptor gene results in osteopetrosis, mononuclear phagocyte deficiency, increased primitive progenitor cell frequencies, and reproductive defects. Blood 2002; 99: 111–120.
Wang X, Hochhaus A, Kantarjian HM, Agrawal S, Roy A, Pfister M et al. Dasatinib pharmacokinetics and exposure-response (E-R): relationship to safety and efficacy in patients (pts) with chronic myeloid leukemia (CML). J Clin Oncol 2008; 26 (Suppl): 3590.
Xing L, Venegas AM, Chen A, Garrett-Beal L, Boyce BF, Varmus HE et al. Genetic evidence for a role for Src family kinases in TNF family receptor signaling and cell survival. Genes Dev 2001; 15: 241–253.
Lowe C, Yoneda T, Boyce BF, Chen H, Mundy GR, Soriano P . Osteopetrosis in Src-deficient mice is due to an autonomous defect of osteoclasts. Proc Natl Acad Sci USA 1993; 90: 4485–4489.
Boyce BF, Yoneda T, Lowe C, Soriano P, Mundy GR . Requirement of pp60c-src expression for osteoclasts to form ruffled borders and resorb bone in mice. J Clin Invest 1992; 90: 1622–1627.
Fitter S, Dewar AL, Kostakis P, To LB, Hughes TP, Roberts MM et al. Long-term imatinib therapy promotes bone formation in CML patients. Blood 2008; 111: 2538–2547.
Berman E, Nicolaides M, Maki RG, Fleisher M, Chanel S, Scheu K et al. Altered bone and mineral metabolism in patients receiving imatinib mesylate. N Engl J Med 2006; 354: 2006–2013.
Grey A, O'Sullivan S, Reid IR, Browett P . Imatinib mesylate, increased bone formation, and secondary hyperparathyroidism. N Engl J Med 2006; 355: 2494–2495.
Acknowledgements
We wish to thank Lee Anne Griffiths, Francis Lee and Richard Smykla from Bristol-Myers Squibb for the provision of dasatinib drug and helpful discussions.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Vandyke, K., Dewar, A., Farrugia, A. et al. Therapeutic concentrations of dasatinib inhibit in vitro osteoclastogenesis. Leukemia 23, 994–997 (2009). https://doi.org/10.1038/leu.2008.356
Published:
Issue Date:
DOI: https://doi.org/10.1038/leu.2008.356
This article is cited by
-
Combination of subtherapeutic anti-TNF dose with dasatinib restores clinical and molecular arthritogenic profiles better than standard anti-TNF treatment
Journal of Translational Medicine (2021)
-
Dasatinib: A Review in Pediatric Chronic Myeloid Leukemia
Pediatric Drugs (2018)
-
The Src family kinase inhibitor dasatinib delays pain-related behaviour and conserves bone in a rat model of cancer-induced bone pain
Scientific Reports (2017)
-
A randomized phase II study of cediranib alone versus cediranib in combination with dasatinib in docetaxel resistant, castration resistant prostate cancer patients
Investigational New Drugs (2014)
-
Targeting Bone Metastases: New Drugs for New Targets
Clinical Reviews in Bone and Mineral Metabolism (2013)